Current trends on cannabidiol delivery systems : where are we and where are we going?
INTRODUCTION: Cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective.
AREAS COVERED: This review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use.
EXPERT OPINION: Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 18(2021), 11 vom: 17. Nov., Seite 1577-1587 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramalho, Ízola Morais de Medeiros [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19GBJ60SN5 |
|---|
| Anmerkungen: |
Date Completed 08.11.2021 Date Revised 08.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425247.2021.1952978 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327989084 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327989084 | ||
| 003 | DE-627 | ||
| 005 | 20231225202015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2021.1952978 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM327989084 | ||
| 035 | |a (NLM)34253133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramalho, Ízola Morais de Medeiros |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current trends on cannabidiol delivery systems |b where are we and where are we going? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2021 | ||
| 500 | |a Date Revised 08.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective | ||
| 520 | |a AREAS COVERED: This review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use | ||
| 520 | |a EXPERT OPINION: Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Nanolipospheres | |
| 650 | 4 | |a conjugates | |
| 650 | 4 | |a ethosomes | |
| 650 | 4 | |a inclusion complex | |
| 650 | 4 | |a microparticles | |
| 650 | 4 | |a nanocrystals | |
| 650 | 4 | |a nanoparticles | |
| 650 | 7 | |a Cannabidiol |2 NLM | |
| 650 | 7 | |a 19GBJ60SN5 |2 NLM | |
| 700 | 1 | |a Pereira, Daniel Torres |e verfasserin |4 aut | |
| 700 | 1 | |a Galvão, Giovanna Brunelly Lima |e verfasserin |4 aut | |
| 700 | 1 | |a Freire, Danielle Teixeira |e verfasserin |4 aut | |
| 700 | 1 | |a Amaral-Machado, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Alencar, Éverton do Nascimento |e verfasserin |4 aut | |
| 700 | 1 | |a Egito, Eryvaldo Socrates Tabosa do |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 18(2021), 11 vom: 17. Nov., Seite 1577-1587 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:11 |g day:17 |g month:11 |g pages:1577-1587 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2021.1952978 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 11 |b 17 |c 11 |h 1577-1587 | ||